Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.

In Silico Lead Generation Approaches In Multi-Target Drug Discovery

In-Silico Approaches to Multi-target Drug Discovery

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Can an in silico drug-target search method be used to probe potential mechanisms of medicinal plant ingredients?

Computer Aided Multi-target Drug Design, Multi-target Virtual Screening

A Guide to In Silico Drug Design

Augmenting Hit Identification by Virtual Screening Techniques in Small Molecule Drug Discovery

In silico design of small molecules

In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery

Computer Aided Drug Design for Multi-Target Drug Design: SAR /QSAR, Molecular Docking and Pharmacophore Methods.

In Silico Methods for Identification of Potential Active Sites of Therapeutic Targets

Deep Lead Optimization: Leveraging Generative AI for Structural Modification

Targeted Molecular Diversity in Drug Discovery: Integration of Structure-Based Design and Combinatorial Chemistry

Combined strategies in structure-based virtual screening

Guided Multi-objective Generative AI to Enhance Structure-based Drug Design

Computational Multitarget Drug Design.

In-silico Target Prediction by Ensemble Chemogenomic Model Based on Multi-Scale Information of Chemical Structures and Protein Sequences.

Hit me with your best shot: Integrated hit discovery for the next generation of drug targets

Multiple target screening method for robust and accurate in silico ligand screening

Structure-based drug design: From nucleic acid to membrane protein targets

Computer-Aided Drug Design: Lead Discovery And Optimization